Is it time to transition?: IV to PO for severe infections

Rochester, NY US
October 17, 2019

This activity will briefly review the OVIVA and POET trials that directly assessed the partial use of oral antibiotics for the treatment of osteomyelitis and left-sided endocarditis vs remaining on IV therapy for the duration of therapy. It will also briefly review recent literature assessing the early transition to oral step-down therapy in the treatment of gram positive and gram negative bloodstream infections. It will address which clinical scenarios would be most appropriate for an early transition to oral therapy. In addition to covering the therapeutic appropriateness of oral antibiotic therapy for the treatment of severe infections, the presentation will review the pharmacokinetics of oral antibiotic agents in order to assess the appropriateness of certain oral agents over others. A brief discussion on the implications that this change in practice can have on antimicrobial stewardship and OPAT services will take place. This information will help pharmacists to decide when they can make an intervention to transition a patient to oral antibiotics for the treatment of these severe infections.

Target Audience

  • Pharmacists

Learning Objectives

Pharmacist learning objectives

  1. Compare the pharmacokinetic properties of certain oral antibiotics and their usefulness in treating more severe infections
  2. Review data supporting the early transition from IV to PO antibiotics for the treatment of osteomyelitis, endocarditis, and bloodstream infections Discuss the literature supporting the use and place in therapy for the pharmacological options in the management of delirium
  3. Develop an evidence-based recommendation for the use of oral antibiotics in severe infections Identify the dosage forms of the pharmacological options for the management of delirium

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 General CEU – Attendance
Course opens: 
Course expires: 
Event starts: 
10/17/2019 - 12:00pm CDT
Event ends: 
10/17/2019 - 1:00pm CDT
University of Rochester Medical Center
601 Elmwood Ave.
Rochester, NY 14642
United States
Relevant financial relationships: Planning committee members, reviewer and presenters have nothing to disclose
Planning committee members
Jessa Brenon, PharmD, BCPS
PGY-2 Infectious Disease Pharmacy Resident
University of Rochester Medical Center
Kelly Pillinger, PharmD, BCIDP
Infectious Diseases Clinical Pharmacy Specialist
University of Rochester Medical Center
Course reviewer
Katrina Harper, PharmD, MBA, BCPS, DPLA
Senior Clinical Manager
Jessa Brenon, PharmD, BCPS
PGY-2 Infectious Disease Pharmacy Resident
University of Rochester Medical Center


Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and University of Rochester Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-19-195-L01-P
Universal Activity Number: JA0006103-9999-19-195-L01-T
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 General CEU – Attendance


Please login or register to take this course.